Skip to main content Back to Top

Keeping Pace with the Guidelines. C diff Past, Present, and Future

Broadcast Date: October 8, 2022


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Learn from experts in the field on treatment and management of C diff infection. Topics will include treatment plans and management strategies for our patients.


Stuart JohnsonStuart Johnson is an Infectious Disease Clinician and Researcher at the Hines VA Hospital and a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center in Maywood, Illinois. His main research interest and focus has involved the epidemiology, pathogenesis, and treatment of Clostridioides difficile infection (CDI). He is the Chair of the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) CDI Guidelines Committee for a focused update on management of CDI.

Kevin GareyKevin W. Garey, PharmD, MS, FASHP, is Professor and Chair of the Department of Pharmacy Practice and Translational Research at the University of Houston College of Pharmacy in Houston, Texas. Dr. Garey is also Adjunct Professor at the University of Texas School of Public Health and Clinical Specialist and Researcher at Baylor St. Luke’s Medical Center in Houston. He is a member of the Infectious Diseases Society of American (IDSA) Standards and Practice Guidelines Committee and is a member of the IDSA-Society of Healthcare Epidemiology of America (SHEA) practice guidelines for C. difficile infection (CDI). Dr. Garey's research, supported by the National Institute of Health, the Centers for Disease Control and Prevention, and the pharmaceutical industry, involves clinical and translational research in healthcare-associated infections including post-surgical infections, candidemia, and CDI.


Relevant Financial Relationship Disclosures

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. 


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Provided by ASHP
Supported by an educational grant from Merck